Archive: Company News
Company News: New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019
– Several scientific conference contributions outline benefits of U.S. FDA-cleared Unyvero LRT Application Cartridge in both endotracheal aspirate and bronchoalveolar lavage samples
– Study shows that Unyvero LRT has potential to support antibiotic stewardship and may reduce time to actionable clinical results by more than two days
Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA Inc. “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that new data on its Unyvero System and LRT Application Cartridge for pneumonia will be presented at the upcoming ASM Microbe Conference, June 20-24, 2019, in San Francisco, CA, USA. Read more…
Company News: Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples
– Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective (retrospective) sample cohort
– U.S. FDA 510(k) submission for Unyvero LRT BAL Application Cartridge in preparation
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced key data from its successfully completed Unyvero LRT clinical performance evaluation study for BAL samples. Read more…
Company News: Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
– Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing
– Yorkville to provide funding of EUR 1.5 million to Curetis
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Curetis will receive another EUR 6.5 million in gross proceeds under two financing facilities. Read more…
Company News: Curetis Announces Financial Results for the First Three Months of 2019
– Total year-on-year revenue growth of approximately 45%
– Successful implementation of corporate re-organization and significant reduction of cost base
– Exclusive pan-European distribution partnership with A. Menarini Diagnostics
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first three months ended March 31, 2019, and provided a business update for 2019. Read more…